Synonyms: APO-66 | CP20 | Ferriprox®
deferiprone is an approved drug (EMA (1999), FDA (2011))
Compound class:
Synthetic organic
Comment: Deferiprone is an iron-chelating drug.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Patients with thalassaemia often require repeated blood transfusions to maintain red blood cell levels, but this type of treatment can lead to potentially fatal iron overload. |
Mechanism Of Action and Pharmacodynamic Effects |
Deferiprone chelates the excess iron in thalassemia patients [1], and effects its removal and excretion. |
External links |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |